FindTrial
Sign In

Pilot Study of Quantitative Analysis of Brain MRI Combined with [18F]FDG PET Metabolic Imaging for Comparative Evaluation and Diagnostic Performance Assessment in Alzheimer's Disease

Pilot Study of Quantitative Analysis of Brain MRI Combined with [18F]FDG PET Metabolic Imaging for Comparative Evaluation and Diagnostic Performance Assessment in Alzheimer's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20260709001
Enrollment
30
Registered
2026-07-09
Start date
2025-06-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive complaints or clinically suspected neurodegenerative disease Alzheimer disease

Interventions

AD,non-AD
Diagnostic,Diagnostic

Sponsors

Chulabhorn Royal Academy (CRA), Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria were: 1) cognitive complaints or clinically suspected neurodegenerative disease 2) brain MRI with Heuron AD analysis and FDG PET performed within a 90-day interval 3) complete quantitative data from both PMOD and MIM analyses.

Exclusion criteria

Exclusion criteria: Patients with major structural brain lesions (large infarctions or primary brain tumors)

Design outcomes

Primary

MeasureTime frame
Diagnostic accuracy 50 minutes after FDG injection SUVR, AI Atrophy Index—

Secondary

MeasureTime frame
Correlateion 50 minutes after FDG injection SUVR, AI Atrophy Index—

Countries

Thailand

Contacts

Public ContactNatchaphorn Onthaworn

Chulabhorn Hospital, Chulabhorn Royal Academy (CRA)

natchaphorn.ont@cra.ac.th025743355

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026